144 related articles for article (PubMed ID: 33164584)
21. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
22. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia.
Rigano P; Rodgers GP; Renda D; Renda MC; Aquino A; Maggio A
Hemoglobin; 2001 Feb; 25(1):9-17. PubMed ID: 11300353
[TBL] [Abstract][Full Text] [Related]
23. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
24. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
Ansari SH; Hussain Z; Zohaib M; Parveen S; Kaleem B; Qamar H; Adil O; Khan MT; Shamsi TS
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e77-e83. PubMed ID: 33710118
[TBL] [Abstract][Full Text] [Related]
25. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
26. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
27. The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.
Kosaryan M; Zafari M; Alipur A; Hedayatizadeh-Omran A
Hemoglobin; 2014; 38(4):262-71. PubMed ID: 25023087
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
[TBL] [Abstract][Full Text] [Related]
29. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
30. In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea.
Mahdavi MR; Pourfarzad F; Kosaryan M; Akbari MT
Iran J Public Health; 2017 Jul; 46(7):948-956. PubMed ID: 28845406
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.
Bordbar MR; Silavizadeh S; Haghpanah S; Kamfiroozi R; Bardestani M; Karimi M
Iran Red Crescent Med J; 2014 Jun; 16(6):e18028. PubMed ID: 25068055
[TBL] [Abstract][Full Text] [Related]
32. Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy.
Kattamis A
J Pediatr Hematol Oncol; 2007 Nov; 29(11):729-30. PubMed ID: 17984687
[No Abstract] [Full Text] [Related]
33. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
Dehury S; Purohit P; Patel S; Meher S; Kullu BK; Sahoo LK; Patel NK; Mohapatra AK; Das K; Patel DK
Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
[TBL] [Abstract][Full Text] [Related]
34. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
35. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
37. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
Kohli-Kumar M; Marandi H; Keller MA; Guertin K; Hvizdala E
J Pediatr Hematol Oncol; 2002 Dec; 24(9):777-8. PubMed ID: 12468925
[TBL] [Abstract][Full Text] [Related]
38. Inducing indel mutation in the SOX6 gene by zinc finger nuclease for gamma reactivation: An approach towards gene therapy of beta thalassemia.
Modares Sadeghi M; Shariati L; Hejazi Z; Shahbazi M; Tabatabaiefar MA; Khanahmad H
J Cell Biochem; 2018 Mar; 119(3):2512-2519. PubMed ID: 28941328
[TBL] [Abstract][Full Text] [Related]
39. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
